Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 4/20 | 0.63 |
| ▸ | CCR9 | P51686 | 15/20 | 0.59 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.57 |
| ▸ | CCR2 | P41597 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4649541 | 0.90 | HSD17B2 (0.67) | HSD17B2CCR9SLC22A12CCR2 | |
| SCHEMBL1130076 | 0.88 | HSD17B2 (0.64) | HSD17B2CCR9CCR2 | |
| SCHEMBL4649590 | 0.87 | SLC22A12 (0.63) | HSD17B2CCR9SLC22A12CCR2 | |
| SCHEMBL4651006 | 0.85 | APP (0.57) | CCR9SLC22A12CCR2 | |
| SCHEMBL4649581 | 0.81 | HSD17B2 (0.63) | HSD17B2CCR9SLC22A12 | |
| SCHEMBL2970692 | 0.80 | HSD17B2 (0.67) | HSD17B2CCR9CCR2 | |
| SCHEMBL2616470 | 0.80 | HSD17B2 (0.67) | HSD17B2CCR9CCR2 | |
| SCHEMBL2968297 | 0.80 | HSD17B2 (0.67) | HSD17B2CCR9CCR2 | |
| SCHEMBL23141320 | 0.79 | SLC22A12 (0.59) | SLC22A12CCR2 | |
| SCHEMBL31046878 | 0.79 | SLC22A12 (0.59) | SLC22A12CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275114-A1 | Inhibitors of Ccr9 Activity | NOVARTIS AG (CH) | 2008-11-06 | — | — | US | claimed |
| EP-1966131-A1 | INHIBITORS OF CCR9 ACTIVITY | Novartis Pharma AG (CH) | 2008-09-10 | — | — | EP | claimed |
| WO-2007071443-A1 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | claimed |
| US-7781481-B2 | N-arylsulfonyl-2,3-dihydro-1H-indoles and the use thereof as CCR9 inhibitors | NOVARTIS AG (CH) | 2010-08-24 | — | — | US | disclosed |
| US-7759390-B2 | chemokine receptor 9(CCR9) antagonists such as, 5-Chloro-thiophene-2-sulfonic acid (4-cyano-2-methyl-phenyl)-amide, used for treating autimmune and inflammatory diseases, transplantat rejection and cancer | NOVARTIS AG (CH) | 2010-07-20 | — | — | US | disclosed |
| US-20080312313-A1 | Inhibitors of Ccr9 Activity | CARBALLIDO HERRERA JOSE M | 2008-12-18 | — | — | US | disclosed |
| US-20080300295-A1 | Inhibitors of Ccr9 Activity | NOVARTIS AG (CH) | 2008-12-04 | — | — | US | disclosed |
| US-20080275114-A1 | Inhibitors of Ccr9 Activity | NOVARTIS AG (CH) | 2008-11-06 | — | — | US | disclosed |
| US-20080269312-A1 | Inhibitors of Ccr9 Activity | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
| EP-1968966-A1 | INHIBITORS OF CCR9 ACTIVITY | Novartis AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| EP-1968939-A2 | INHIBITORS OF CCR9 ACTIVITY | Novartis AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| EP-1966182-A1 | INHIBITORS OF CCR9 ACTIVITY | Novartis AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| EP-1966131-A1 | INHIBITORS OF CCR9 ACTIVITY | Novartis Pharma AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071440-A1 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007071443-A1 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007071442-A2 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007071441-A1 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312313-A1 | Inhibitors of Ccr9 Activity | CCR9, CCR1, CCR4 | HSD17B2 1594/4885CCR9 1/4885SLC22A12 2659/4885 |
| US-20080300295-A1 | Inhibitors of Ccr9 Activity | CCR9, CCR1, CCR4 | HSD17B2 1969/4885CCR9 1/4885SLC22A12 2846/4885 |
| US-20080269312-A1 | Inhibitors of Ccr9 Activity | CCR9, CCR1, CCR4 | HSD17B2 3145/4885CCR9 1/4885SLC22A12 4049/4885 |
| US-20080275114-A1 | Inhibitors of Ccr9 Activity | CCR9, CCR1, CCR4 | HSD17B2 1512/4885CCR9 1/4885SLC22A12 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.